hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06371326, orgStudyIdInfo id: BJQLZT002004, briefTitle: A Study of ZT002 Injection in Participants With Overweight or Obesity, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-11-21, primaryCompletionDateStruct date: 2024-08-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Beijing QL Biopharmaceutical Co.,Ltd, class: INDUSTRY, descriptionModule briefSummary: This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity., conditionsModule conditions: Overweight or Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: ZT002 Injection, interventions name: Placebo, outcomesModule primaryOutcomes measure: Safety and tolerability of a multiple escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in MAD Cohorts. Number of participants with treatment-emergent adverse events., primaryOutcomes measure: Safety and tolerability of a multiple escalation dose of ZT002 through the incidence severity of serious adverse events in MAD Cohorts. Number of participants with serious adverse events., secondaryOutcomes measure: The Pharmacokinetics (PK) profile of a multiple escalation dose of ZT002 in participants with overweight or obesity., secondaryOutcomes measure: The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in participants with overweight or obesity., secondaryOutcomes measure: The anti-drug antibody (ADA) response through testing serum or plasma of the participants post-dosing., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: First Affiliated Hospital of Bengbu Medical College, city: Bengbu, country: China, geoPoint lat: 32.94083, lon: 117.36083, hasResults: False
protocolSection identificationModule nctId: NCT06371313, orgStudyIdInfo id: GuangdongWCH-LiLi03, briefTitle: Endocrine, Metabolic and Inflammatory Characteristics of Offspring of Mothers With PCOS Hyperandrogenism, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-03-05, completionDateStruct date: 2024-03-05, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Guangdong Women and Children Hospital, class: OTHER, descriptionModule briefSummary: This study is a cross-sectional study to explore the endocrine metabolism and inflammatory characteristics of the offspring of mothers with PCOS hyperandrogenism, in order to provide a theoretical basis for finding the cause of PCOS., conditionsModule conditions: PCOS, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 42, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Testosterone, primaryOutcomes measure: Androstenedione, primaryOutcomes measure: Dehydroepiandrosterone Sulfate, primaryOutcomes measure: Sex Hormone Hinding Globulin, primaryOutcomes measure: Free Androgen Index, primaryOutcomes measure: Fasting Insulin, primaryOutcomes measure: White Blood Cell Count, primaryOutcomes measure: Neutrophil Count, primaryOutcomes measure: High-sensitivity C-reactive Protein, primaryOutcomes measure: Interleukin-6, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Guangdong Women and Children Hosptial, city: Guanzhou, state: Guangdong, zip: 511400, country: China, hasResults: False
protocolSection identificationModule nctId: NCT06371287, orgStudyIdInfo id: 64696022.1.0000.5346, briefTitle: Effect of Musical Auditory Training on Subjects With Tinnitus Disorder, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-20, primaryCompletionDateStruct date: 2024-08-10, completionDateStruct date: 2025-02-10, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Universidade Federal de Santa Maria, class: OTHER, descriptionModule briefSummary: Among the theories of tinnitus generation, there is that of central neuroplastic changes, which reports the association between changes and reorganization that occur in central auditory pathways and impacts on associated areas due to the altered neural signal. Auditory training modifies these altered pathways through auditory exercises, which provoke positive neuroplasticity. Musical auditory training is a proposal to stimulate auditory, cognitive and metalinguistic skills with activities focused on musicality. Therefore, the objective of this study is to verify the effect of musical auditory training (MAT) on the neuroplasticity of the auditory system and the perception of tinnitus disorder in young adults., conditionsModule conditions: Tinnitus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Treinamento Auditivo Musical, interventions name: Placebo, outcomesModule primaryOutcomes measure: Changes in latency of the long latency auditory evoked potential (LLAEP), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Universidade Federal de Santa Maria, status: RECRUITING, city: Santa Maria, state: RS, zip: 97.105-970, country: Brazil, contacts name: Dayane Domeneghini Didoné, role: CONTACT, phone: 553220-9362, email: dayane.didone@ufsm.br, contacts name: Dayane Domeneghini Didoné D Dayane Domeneghini Didoné, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: -29.68417, lon: -53.80694, locations facility: Universidade Federal de Santa Maria, status: RECRUITING, city: Santa Maria, state: RS, zip: 97.105-970, country: Brazil, contacts name: Dayane D Didoné, Professora, role: CONTACT, phone: 553220-9362, email: dayane.didone@ufsm.br, contacts name: Christine G Schumacher, Mestranda, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: -29.68417, lon: -53.80694, hasResults: False
protocolSection identificationModule nctId: NCT06371274, orgStudyIdInfo id: ZYYY-IIT-TNBC-001, briefTitle: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: First Affiliated Hospital of Zhejiang University, class: OTHER, collaborators name: Shanghai Longfine Biotechnology Co., Ltd., collaborators name: TopAlliance, descriptionModule briefSummary: To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy., conditionsModule conditions: Triple-negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: ATRA, interventions name: Toripalimab, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Overall Survival (OS), otherOutcomes measure: Incidence of Treatment-Emergent Adverse events as assessed by NCI-CTCAE 5.0, otherOutcomes measure: Exploratory biomarkers-peripheral blood lymphocyte analysis, otherOutcomes measure: Exploratory biomarkers-Serum Metabolomics Analysis, otherOutcomes measure: Exploratory biomarkers-Fecal Microbiota Analysis, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The first affiliated hospital, Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang Province, P.R. China, zip: 310003, country: China, contacts name: Meihua Lin, MS, role: CONTACT, contacts name: Jian Liu, MS, role: PRINCIPAL_INVESTIGATOR, contacts name: Xiaochen Zhang, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06371248, orgStudyIdInfo id: 2850, briefTitle: Steady Feet: Preventing Falls in the Community, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-11-19, primaryCompletionDateStruct date: 2019-12-20, completionDateStruct date: 2019-12-20, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Changi General Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to examine the feasibility of Steady Feet, a three-month community-based falls prevention exercise program., conditionsModule conditions: Fall, conditions: Feasibility, conditions: Older Adults, conditions: Exercise, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 65, type: ACTUAL, armsInterventionsModule interventions name: Steady Feet, interventions name: Usual care for fall prevention, outcomesModule primaryOutcomes measure: Short Physical Performance Battery (SPPB), secondaryOutcomes measure: CONFbal, secondaryOutcomes measure: Six-minute walk test (6MWT), secondaryOutcomes measure: Timed up and go (TUG), secondaryOutcomes measure: Four square step test (FSST), secondaryOutcomes measure: Feedback and satisfaction survey, otherOutcomes measure: Attendance and completion rates, otherOutcomes measure: Safety of Steady Feet, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Changi General Hospital, city: Singapore, zip: 529889, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06371235, orgStudyIdInfo id: 2024-A00739-38, briefTitle: Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier, acronym: Pregiferon, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: CerbaXpert, class: OTHER, descriptionModule briefSummary: The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother's IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence of these autoantibodies and in those seropositive during the pregnancy., conditionsModule conditions: Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Pregiferon, outcomesModule primaryOutcomes measure: Frequency of placental transfer of self-Ab directed against IFN alpha from mother to newborn., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06371222, orgStudyIdInfo id: BSMMU/2023/6502, briefTitle: Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-01-31, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, class: OTHER, descriptionModule briefSummary: Mitral stenosis, a condition characterized by narrowing of the mitral valve orifice, remains a significant cause of morbidity and mortality worldwide, particularly in regions where rheumatic fever is endemic. Despite advancements in medical and surgical management, patients with mitral stenosis often suffer from symptoms such as dyspnea, fatigue, and reduced exercise tolerance, significantly impacting their quality of life (QoL) \[1\].One of the hallmark features of mitral stenosis is the development of sinus rhythm, which can be associated with elevated heart rates due to decreased diastolic filling time and compensatory mechanisms to maintain cardiac output. Persistent tachycardia in patients with mitral stenosis contributes to increased myocardial oxygen demand, exacerbating symptoms and potentially leading to adverse outcomes \[2\].In recent years, ivabradine, a selective inhibitor of the If current in the sinoatrial node, has emerged as a promising therapeutic option for controlling heart rate in various cardiovascular conditions, including chronic heart failure and ischemic heart disease \[3\]. By specifically targeting the cardiac pacemaker cells, ivabradine reduces heart rate without affecting myocardial contractility or conduction, offering a unique mechanism of heart rate control compared to traditional beta-blockers or calcium channel blockers \[4\].However, the role of ivabradine in patients with mitral stenosis in sinus rhythm remains uncertain, and there is limited evidence regarding its efficacy and impact on QoL in this specific patient population. Therefore, the aim of this randomized controlled trial (RCT) is to investigate the effects of ivabradine on heart rate control and QoL in patients with mitral stenosis in sinus rhythm., conditionsModule conditions: Mitral Stenosis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: RCT, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ACTUAL, armsInterventionsModule interventions name: Ivabradine, interventions name: Beta blocker, outcomesModule primaryOutcomes measure: effect of ivabradine in MS patients, secondaryOutcomes measure: quality of life of MS patients, eligibilityModule sex: ALL, minimumAge: 17 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: BSMMU, city: Dhaka, zip: 1200, country: Bangladesh, geoPoint lat: 23.7104, lon: 90.40744, hasResults: False
protocolSection identificationModule nctId: NCT06371183, orgStudyIdInfo id: AOMSaidB, briefTitle: A Comparative Study of Clinical, Endoscopic and Histopathological Features of Colitis in Children on June 2024, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-05-30, completionDateStruct date: 2027-05-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: A Comparative study of clinical, endoscopic and histopathological features of colitis in children, conditionsModule conditions: Role of Ileoscopy in Diagnosis of Colitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients who complaining of lower GI manifestations, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 196, type: ESTIMATED, armsInterventionsModule interventions name: Colonoscope, outcomesModule primaryOutcomes measure: Role of ileoscopy in diagnosis of colitis, secondaryOutcomes measure: To correlate clinical manifestations by colonoscopic picture, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06371170, orgStudyIdInfo id: CCPC- 001/22, briefTitle: Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliero, Universitaria Ospedali Riuniti, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (\< 16 years old) diagnosed with intracardiac thrombosis. The main question it aims to answer is: Does rivaroxaban treatment resolve the thrombosis during a 3-month treatment?Participants already taking rivaroxaban as part of their regular medical care for thrombosis resolution. They will undergo monthly visits to check that the treatment is progressing correctly and that no major bleeding has occurred. After 3 months of treatment, they will repeat the radiological imaging investigation to verify the actual resolution of the thrombosis., conditionsModule conditions: Intracardiac Thrombus, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Rivaroxaban, outcomesModule primaryOutcomes measure: Thrombus resolution, secondaryOutcomes measure: Bleeding, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: CCPC, status: RECRUITING, city: Ancona, state: Marche, zip: 60123, country: Italy, contacts name: Francesco Bianco, M.D., role: CONTACT, phone: +39 071 596 5316, email: francesco.bianco@ospedaliriuniti.marche.it, geoPoint lat: 43.5942, lon: 13.50337, hasResults: False
protocolSection identificationModule nctId: NCT06371105, orgStudyIdInfo id: 014_2018, briefTitle: Aquatic_Training in Obese Women, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-01-02, primaryCompletionDateStruct date: 2019-03-30, completionDateStruct date: 2019-03-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: University of Taipei, class: OTHER, descriptionModule briefSummary: This study aims to assess the effects of 10-week water-based aerobic training (thrice a week) on anthropometrics, biochemicals, cardiovascular parameters, and explosive strength in young overweight and obese women. The findings indicate that water-based aerobic training could be a useful program to enhance body composition, biochemical, cardiovascular, and explosive strength parameters in young overweight and obese women compared to inactive persons, conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 31, type: ACTUAL, armsInterventionsModule interventions name: 10-week water-based aerobic training, outcomesModule primaryOutcomes measure: fasting glycemia in millimoles per liter, primaryOutcomes measure: total cholesterol in millimoles per liter, primaryOutcomes measure: high-density lipoprotein cholesterol in millimoles per liter, primaryOutcomes measure: low-density lipoprotein cholesterol in millimoles per liter, primaryOutcomes measure: triglyceride concentrations in millimoles per liter, primaryOutcomes measure: systolic blood pressure in millimeters of mercury, primaryOutcomes measure: diastolic blood pressure in millimeters of mercury, primaryOutcomes measure: heart rate in beat per minute, primaryOutcomes measure: fasting glycemia in millimoles per liter, primaryOutcomes measure: total cholesterol in millimoles per liter, primaryOutcomes measure: high-density lipoprotein cholesterol in millimoles per liter, primaryOutcomes measure: low-density lipoprotein cholesterol in millimoles per liter, primaryOutcomes measure: triglyceride concentrations in millimoles per liter, primaryOutcomes measure: systolic blood pressure in millimeters of mercury, primaryOutcomes measure: diastolic blood pressure in millimeters of mercury, primaryOutcomes measure: heart rate in beat per minute, secondaryOutcomes measure: countermovement jump in centimetres, secondaryOutcomes measure: squat jump in centimeters, secondaryOutcomes measure: chest 3-kg medicine ball throw in meters, secondaryOutcomes measure: countermovement jump in centimetres, secondaryOutcomes measure: squat jump in centimeters, secondaryOutcomes measure: chest 3-kg medicine ball throw in meters, eligibilityModule sex: FEMALE, minimumAge: 29 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Exercise and Health Sciences, University of Taipei, city: Taipei, zip: 11153, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06371092, orgStudyIdInfo id: 2023/01, briefTitle: Efficacy of a Desensitizing Agent During At-home Bleaching, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-31, primaryCompletionDateStruct date: 2023-02-22, completionDateStruct date: 2023-03-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: University of Santiago de Compostela, class: OTHER, descriptionModule briefSummary: The main objective of this study is to evaluate if the use of UltraEZ during at-home bleaching treatment is effective in reducing tooth sensitivity, as well as doesn't affect the degree of tooth bleaching., conditionsModule conditions: Sensitivity, Tooth, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, triple-blind clinical trial, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: UltraEZ, interventions name: Placebo, outcomesModule primaryOutcomes measure: Questionnaire of dental sensitivity, secondaryOutcomes measure: Shade evaluation with a dental spectrophotometer, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: School of Medicine and Dentistry, city: Santiago De Compostela, state: A Coruña, zip: 15705, country: Spain, geoPoint lat: 42.88052, lon: -8.54569, hasResults: False